Mesenchymal Stem Cell therapy in COVID19

Mesenchymal stem cell utilization in reducing complications and enhancing pneumonia healing in patients infected with 2019-nCoV (phase I clinical trial)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200325046860N2

Enrollment

Registered

2020-04-01

Start date

2020-03-28

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Disease. COVID-19 Disease

Interventions

Treatment group: Patients with confirmed COVID-19 infection who in addition to their current treatment will be infused with 70 million mesenchymal stem cell day 0, 3 6 , infusion time 30 min 4..

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Male or female, aged at 18 years (including) -70 years old Laboratory confirmation of 2019-nCoV infection by reverse-transcription polymerase chain reaction (RT-PCR) from any diagnostic sampling source Pneumonia that is judged by chest radiograph or computed tomography. Resp rate> 30, o2 sat < 93%,

Exclusion criteria

Exclusion criteria: Pregnancy, lactation Patients with malignant tumor, other serious systemic diseases and psychosis Patients who are participating in other clinical trials; Inability to provide informed consent Co-Infection of HIV, tuberculosis, influenza virus

Design outcomes

Primary

Measure	Time frame
Respiratory function of patients. Timepoint: Every 24 hours after MSC infusion. Method of measurement: Clinical, lab test , CT scan.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHasan Abolghasemi

Bagheiat-allah University of Medical Sciences

h.abolghasemi.ha@gmail.com+98 21 8126 3799

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026